Treatment of Hypertrophic Cardiomyopathy with Left Ventricular Mid-Cavity Obstruction

Left ventricular mid-cavity obstruction is a distinct variant of hypertrophic cardiomyopathy (HCM) in which the obstruction occurs at the mid-ventricular level rather than the outflow tract. This anatomical pattern defines a patient population with specific treatment considerations.

Clinical Scenario

Patients with LV mid-cavity obstruction are initially managed with high-dose beta-blockers, verapamil, or diltiazem; however, the response to these agents is often suboptimal, leaving obstruction inadequately relieved in a meaningful proportion of patients.

Treatment Approach

When medical therapy is insufficient, surgical myectomy is a recognized option for relieving mid-ventricular obstruction — the specific approach and complete protocol are available in the full regimen.

Approach selection criteria, procedural options, and the complete algorithm are detailed in the full protocol below.

Instant Access to Structured Evidence-Based Regimens

References

Patients with LV mid-cavity obstruction should be treated with high-dose beta-blockers, verapamil, or diltiazem, but the response is often suboptimal.

Limited experience, mostly from single centres, suggests that mid-ventricular obstruction can be relieved by transaortic myectomy, a transapical approach, or combined transaortic and transapical incisions, with good short-term outcomes but uncertain long-term survival.

DOI: 10.1093/eurheartj/ehad194

View source ↗